Abstract: Provided are methods for generating a workflow of a healthcare professional and methods of generating graphical user interfaces (GUI) that display the workflow of the healthcare professional. A workflow of a healthcare professional may include an ordered list of healthcare events associated with the healthcare professional. Each healthcare event in the ordered list may request the attention of the healthcare professional or may provide an indication that the healthcare professional should complete some associated work. Healthcare events may include tasks for the healthcare professional, alerts such as new lab results for patients, scheduled appointments with patients, or appointment requests from patients. The workflow may provide a healthcare professional with, in one user interface all, substantially all, or a majority of the healthcare events that the healthcare professional should be aware to perform their job.

Abstract: Pharmaceutical compositions comprising poorly water-soluble drugs (PSDs) and sucrose acetate isobutyrate (SAIB). The compositions are amorphous solid solutions or amorphous solid dispersions where the PSDs are present in the molecular or the amorphous state in the SAIB. The PSDs in amorphous form in the amorphous solid solutions can be stable against crystallization on exposure to elevated temperature and humidity conditions. Oral dosage forms containing the compositions are characterized by a higher dissolution rate in water, a higher serum maximum concentration (Cmax), and/or a greater area under the curve (AUG) than an equivalent oral dosage form without the SAIB.

Abstract: Systems and method for determining patient prioritization scores for use by healthcare professionals in administering care to patients. Healthcare data of patients is used to determine one or more of a care gap score representing opportunities to improve care of a patient, a risk score representing risks to health of the patient, a change over time in the risk score for the patient, a measure representing a willingness of the patient to receive care, and a prediction of future costs associated with care of the patient. The one or more scores and measures are used to determine a patient prioritization score for the patient. A healthcare professional can be prompted based on the patient prioritization to administer of care to the patient. A graphical user interface (GUI) can be generated that includes the prompt, and the GUI may be provided to a display.

Abstract: In an embodiment, the present disclosure pertains to a stable formulation of a varenicline salt or base form containing composition that prevents or reduces formation of a nitroso impurity until the end of stated expiration or longer. In some embodiments, the composition includes varenicline and at least one pharmaceutical excipient. In some embodiments, the at least one pharmaceutical excipient includes a magnesium salt and at least one of dicalcium phosphate, polyethylene glycol, or polyethylene oxide. In some embodiments, the magnesium salt can include, without limitation, magnesium aluminum silicate, magnesium aluminometasilicate, magnesium carbonate, magnesium oxide, magnesium silicate, magnesium stearate, magnesium sulfate, magnesium trisilicate, and combinations thereof. In some embodiments, a weight ratio of the varenicline to the at least one pharmaceutical excipient ranges from 1 to 99 to 99 to 1% w/w.

Abstract: In an embodiment, the present disclosure pertains to a stable formulation of a primary, secondary, and/or tertiary amino group containing composition that prevents or reduces formation of a nitroso impurity until the end of stated expiration or longer. In some embodiments, the composition includes metformin and at least one pharmaceutical excipient. In some embodiments, the at least one pharmaceutical excipient includes a magnesium salt and at least one of a calcium salt, dicalcium phosphate, polyethylene glycol, or polyethylene oxide. In some embodiments, the magnesium salt can include, without limitation, magnesium aluminum silicate, magnesium aluminometasilicate, magnesium carbonate, magnesium oxide, magnesium silicate, magnesium stearate, magnesium sulfate, magnesium trisilicate, and combinations thereof. In some embodiments, a weight ratio of the drug to the at least one pharmaceutical excipient ranges from 1 to 99 to 99 to 1% w/w.

Abstract: In an embodiment, a drug delivery system and method of use thereof to treat inflammation and bacterial pathogens including multi-drug resistant pathogens, such as MDR-Pseudomonas aeruginosa, or reactive oxygen species in a subject is provided. In some embodiments, the drug delivery system includes a polymeric material, an excepient, an antioxidant agent, and an anti-inflammatory and antimicrobial agent. In some embodiments, the anti-inflammatory and antimicrobial agent is a salt of an anti-inflammatory agent and an antimicrobial agent formulated to provide a combination of antimicrobial and anti-inflammatory action from a single molecule. In some embodiments, the combined anti-inflammatory and antimicrobial agent is a silver salt of ibuprofen. In other embodiments, the combined anti-inflammatory and antimicrobial agent is unmodified, native ibuprofen.

Abstract: Provided are methods for generating a workflow of a healthcare professional and methods of generating graphical user interfaces (GUI) that display the workflow of the healthcare professional. A workflow of a healthcare professional may include an ordered list of healthcare events associated with the healthcare professional. Each healthcare event in the ordered list may request the attention of the healthcare professional or may provide an indication that the healthcare professional should complete some associated work. Healthcare events may include tasks for the healthcare professional, alerts such as new lab results for patients, scheduled appointments with patients, or appointment requests from patients. The workflow may provide a healthcare professional with, in one user interface all, substantially all, or a majority of the healthcare events that the healthcare professional should be aware to perform their job.

Abstract: A eutectic-based self-nanoemulsified drug delivery system (SNEDDS) is formulated from polyoxyl 35 castor oil (Cremophor), medium chain mono- and diglycerides (capmul), essential oils, and a pharmacologically effective drug. The preferred pharmacologically effective drug is a poorly water soluble drug, such as ubiquinone (CoQ10). The SNEDDS can be further incorporated into a powder to produce a solid dosage form. The solid dosage form contains the SNEDDS, a copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), maltodextrin, and microcrystalline cellulose (MCC).

Abstract: This invention focuses not on archiving an increasing number of medical literature articles, but having a defined number of learning modules, which when matched against certain predefined criteria, issue a learning recommendation to a physician. Systems and method embodiments include determining a pattern of medical treatment, analyzing the pattern with current medical data, and recommending, based on the analysis, at least one of a treatment, a continuing medical education, a learning module, and medical literature.

Abstract: A eutectic-based self-nanoemulsified drug delivery system (SNEDDS) is formulated from polyoxyl 35 castor oil (Cremophor), medium chain mono- and diglycerides (capmul), essential oils, and a pharmacologically effective drug. The preferred pharmacologically effective drug is a poorly water soluble drug, such as ubiquinone (CoQ10). The SNEDDS can be further incorporated into a powder to produce a solid dosage form. The solid dosage form contains the SNEDDS, a copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), maltodextrin, and microcrystalline cellulose (MCC).

Abstract: A eutectic-based self-nanoemulsified drug delivery system (SNEDDS) is formulated from polyoxyl 35 castor oil (Cremophor), medium chain mono- and diglycerides (capmul), essential oils, and a pharmacologically effective drug. The preferred pharmacologically effective drug is a poorly water soluble drug, such as ubiquinone (CoQ10). The SNEDDS can be further incorporated into a powder to produce a solid dosage form. The solid dosage form contains the SNEDDS, a copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), maltodextrin, and microcrystalline cellulose (MCC).

Abstract: A eutectic-based self-nanoemulsified drug delivery system (SNEDDS) is formulated from polyoxyl 35 castor oil (Cremophor), medium chain mono- and diglycerides (capmul), essential oils, and a pharmacologically effective drug. The preferred pharmacologically effective drug is a poorly water soluble drug, such as ubiquinone (CoQ10). The SNEDDS can be further incorporated into a powder to produce a solid dosage form. The solid dosage form contains the SNEDDS, a copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), maltodextrin, and microcrystalline cellulose (MCC).

Abstract: A eutectic-based self-nanoemulsified drug delivery system (SNEDDS) is formulated from polyoxyl 35 castor oil (Cremophor), medium chain mono- and diglycerides (capmul), essential oils, and a pharmacologically effective drug or nutraceutical or dietary supplement. The preferred pharmacologically effective drug is a poorly water soluble drug, such as ubiquinone (CoQ10). The SNEDDS can be further incorporated into a powder to produce a solid dosage form. The solid dosage form contains the SNEDDS, a copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), maltodextrin, and microcrystalline cellulose (MCC).

Abstract: A methodology for making joint channel and routing assignments in multi-radio wireless mesh networks that takes into account interference constraints, the number of channels in a network and the number of radio available at each mesh router, and maximizes bandwidth allocation subject to fairness constraints. In particular, the methodology provides for routing, channel assignment and link scheduling in multi-radio mesh wireless networks utilizing a constant factor approximation technique that models the interference and fairness constraints and is able to account for the number of radios at each of the wireless nodes of a wireless mesh network.

Abstract: A method is provided for ordering over a network one or more tests for a medical condition for a patient, the method including the steps of providing to the user over the network one or more tests for the patient that can be selected, allowing a user to select over the network one or more tests, determining whether a constraint exists on ordering any of the selected tests; ordering the selected tests over the network, obtaining a result of each of the ordered tests, and providing an automated evaluation based upon feedback resulting from the ordered tests. Using the methods and systems described, a user, such as a physician, can easily obtain information over a network about a large number of tests and order any of the tests over the network. The server can also obtain payment and related information from the user at the time the one or more tests are ordered.

Abstract: Line system design techniques are provided for use in performing routing and coloring operations associated with one or more demands. In one aspect of the invention, a technique for designing a line system comprises the following steps/operations. A set of one or more demands is obtained for use in computing the line system design. The line system design is then represented as a graph in accordance with a graph coloring operation wherein colors represent bandwidths such that bandwidths are assigned and the one or more demands are routed so as to attempt to achieve a minimum total design cost. The line system being designed may be an optical line system.

Abstract: Dosage forms are identified based on a comparison of surface roughness parameters. One or more of the following surface roughness parameters are measured: 1) mean peak to valley height (Rz); 2) geometric average height from a mean line (Rq); 3) maximum profile peak height (Rp); 4) roughness depth (Rt); 5) and arithmetic mean roughness (Ra). The surface roughness parameters of a first dosage form are determined and compared to the surface roughness parameters of a second dosage form. This method provides a way of “fingerprinting” dosage forms to help identify adulterated and misbranded drugs. In addition, a variety of characteristics relating to composition and process for making the dosage form may be determined by the quantitative method.

Abstract: A method is provided for ordering over a network one or more tests for a condition, the method including: recommending to the user over the network one or more tests based on the provisional diagnosis; providing to the user over the network an analysis of the one or more recommended tests if more than one test is recommended; allowing a user to select over the network one or more of the tests; determining whether a constraint exists on ordering any of the selected tests; ordering each of the selected tests over the network if no constraint exists to obtain each of the selected tests; and obtaining a result of each of the selected tests. Using the methods and systems described, a user, such as a physician, can easily obtain information over a network about a large number of tests and order any of the tests over the network. The server can also obtain payment and related information from the user at the time the one or more tests are ordered.

Abstract: The application discloses a composition and method for an oral dual controlled release formulation of a protein and absorption modifier. The coprecipitation technique for preparation of microcapsules of insulin as a model protein was evaluated and dissolution stability experiments in the presence of trypsin and &agr;-chymotrypsin using chicken and duck ovomucoids as absorption modifiers were performed. The novel formulation improves the bioavailability of the protein with ovomucoids, while conserving the protein structure even after formulation and processing. An optimization design was used to evaluate critical process variables including the rate of addition of polymeric solution, compression pressure, and volume of water with respect to polymeric solution. The novel formulation incorporates controlled release characteristics of both protein and inhibitor to enhance protein stability and bioavailability with less potential for inhibitor concentration-related toxicity.